AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3256808 — intervention group
Group type: EXPERIMENTAL
Intervention: CLOtest
Number of subjects: 175
Study 3256808 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological examination
Number of subjects: 175
Study 7801609 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV DNA detection using a 32P‐labelled dot blot hybridisation assay
Number of subjects: 605
Study 7801609 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alanine aminotransferase (ALT) estimation
Number of subjects: 605
Study 7801609 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ALT with HBV DNA positivity
Number of subjects: 605
Study 7801609 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal ALT levels in DNA-positive samples
Number of subjects: 605
Study 42577 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prostaglandin E2
Number of subjects: 100
Study 42577 — intervention group
Group type: COMPARATOR
Intervention: Buccal tablets of demoxytocin
Number of subjects: 100
Study 30673029 — intervention group
Group type: EXPERIMENTAL
Intervention: Palatal appliance (GI)
Number of subjects: 20
Study 30673029 — intervention group
Group type: COMPARATOR
Intervention: Mandibular appliance (GII)
Number of subjects: 20
Study 29095784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMAC) with bone allograft
Number of subjects: 10
Study 29095784 — intervention group
Group type: COMPARATOR
Intervention: Bone allograft without BMAC (Control Group)
Number of subjects: 10
Study 29095784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMAC) with bone allograft (Test Group)
Number of subjects: 10
Study 26093675 — intervention group
Group type: EXPERIMENTAL
Intervention: People-centered tuberculosis care strategy with educational and counselling sessions, SMS reminders, and phone calls for adherence monitoring.
Number of subjects: 0
Study 26093675 — intervention group
Group type: EXPERIMENTAL
Intervention: People-centered tuberculosis care strategy.
Number of subjects: 0
Study 26093675 — intervention group
Group type: COMPARATOR
Intervention: Standard directly observed treatment strategy (control).
Number of subjects: 0
Study 23629959 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐I with adjunctive IRT
Number of subjects: 40
Study 23629959 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 40
Study 20401752 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymatic hydrolysed collagen (EHC) 10 g daily
Number of subjects: 100
Study 20401752 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine sulphate (GS) 1.5 g
Number of subjects: 100
Study 19141065 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.025%
Number of subjects: 35
Study 19141065 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05%
Number of subjects: 35
Study 17909165 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes self-management program
Number of subjects: 17
Study 17909165 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study 15136679 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 965
Study 15136679 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacute herpetic neuralgia (non-PHN)
Number of subjects: 965
Study 12790943 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment (Group A)
Number of subjects: 100
Study 12790943 — intervention group
Group type: COMPARATOR
Intervention: Closed treatment (Group B)
Number of subjects: 100
Study 9727544 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg once daily)
Number of subjects: 24
Study 9727544 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide mononitrate (ISMN, 50 mg once daily)
Number of subjects: 24
Study 7519764 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg panomifene (PAN)
Number of subjects: 10
Study 7519764 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg panomifene (PAN)
Number of subjects: 10
Study 7519764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7519764 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH and LH (both doses)
Number of subjects: 10
Study 3191339 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 60
Study 3191339 — intervention group
Group type: COMPARATOR
Intervention: No heparin (control)
Number of subjects: 60
Study 31691723 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (500 mg tablet per day)
Number of subjects: 60
Study 31691723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27825697 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional 5‐fluorouracil (FU) chemotherapy
Number of subjects: 282
Study 27825697 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with irinotecan (IRI)
Number of subjects: 282
Study 27825697 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublet chemotherapy (FU + IRI)
Number of subjects: 282
Study 25313534 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian sagittal oblique approach
Number of subjects: 42
Study 25313534 — intervention group
Group type: COMPARATOR
Intervention: Paramedian sagittal approach
Number of subjects: 42
Study 23510513 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CaP) supplementation (plus 1 g calcium/d)
Number of subjects: 10
Study 23510513 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 10
Study 21216868 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax-WN02 vaccine
Number of subjects: 23
Study 18647268 — intervention group
Group type: EXPERIMENTAL
Intervention: Spicy meal (standard meal mixed with 2 g chili)
Number of subjects: 20
Study 18647268 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal with 2 g chili in capsules
Number of subjects: 20
Study 18647268 — intervention group
Group type: COMPARATOR
Intervention: Spicy meal
Number of subjects: 20
Study 18647268 — intervention group
Group type: COMPARATOR
Intervention: Standard meal with chili capsules
Number of subjects: 20
Study 18647268 — intervention group
Group type: COMPARATOR
Intervention: Standard meal
Number of subjects: 20
Study 17207301 — intervention group
Group type: EXPERIMENTAL
Intervention: PercuTwist
Number of subjects: 130
Study 17207301 — intervention group
Group type: COMPARATOR
Intervention: Guide-wire dilating forceps (GWDF)
Number of subjects: 130
Study 17207301 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous dilatational tracheostomy (PDT)
Number of subjects: 130
Study 15508053 — intervention group
Group type: EXPERIMENTAL
Intervention: HFOV
Number of subjects: 52
Study 15508053 — intervention group
Group type: COMPARATOR
Intervention: CMV
Number of subjects: 52
Study 11212591 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 59
Study 11212591 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 59
Study 11212591 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 59
Study 11212591 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 59
Study 11212591 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone
Number of subjects: 59
Study 9601160 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg/day
Number of subjects: 8
Study 9601160 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 120 mg/day
Number of subjects: 8
Study 9601160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8056992 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg daily)
Number of subjects: 249
Study 8056992 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (150 mg daily)
Number of subjects: 249
Study 8056992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 2658581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg or 1,000 mg twice daily
Number of subjects: 48
Study 2658581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin treatment
Number of subjects: 48
Study 31898191 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise intervention group
Number of subjects: 139
Study 31898191 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual lifestyle behaviors)
Number of subjects: 139
Study 31013131 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.018-inch slot bracket system
Number of subjects: 74
Study 31013131 — intervention group
Group type: COMPARATOR
Intervention: 0.022-inch slot bracket system
Number of subjects: 74
Study 28934438 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental malaria
Number of subjects: 473
Study 28934438 — intervention group
Group type: COMPARATOR
Intervention: Peripheral infection without placental sequestration
Number of subjects: 473
Study 28934438 — intervention group
Group type: COMPARATOR
Intervention: No malaria during pregnancy
Number of subjects: 473
Study 25503414 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal education protocol including verbal and written instructions and verbal repetition of instructions (Clinic 1)
Number of subjects: 330
Study 25503414 — intervention group
Group type: COMPARATOR
Intervention: No specific education policy (Clinic 2)
Number of subjects: 330
Study 23456769 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 200 μg for 12 weeks
Number of subjects: 142
Study 23456769 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 400 μg for 12 weeks
Number of subjects: 142
Study 23456769 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 400 μg compared to 200 μg
Number of subjects: 142
Study 23456769 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 400 μg compared to 0 μg
Number of subjects: 142
Study 23456769 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 400 μg
Number of subjects: 142
Study 20705350 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography measurement of epicardial adipose tissue (EAT) thickness
Number of subjects: 120
Study 20705350 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein-cholesterol (LDL-C) measurement
Number of subjects: 120
Study 19244569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 2
Study 19244569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 17105658 — intervention group
Group type: COMPARATOR
Intervention: CQ
Number of subjects: 117
Study 17105658 — intervention group
Group type: EXPERIMENTAL
Intervention: CQ + SP
Number of subjects: 117
Study 17105658 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (45 mg single dose)
Number of subjects: 117
Study 15585774 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric, nutrient-enriched preterm formula
Number of subjects: 37
Study 15585774 — intervention group
Group type: COMPARATOR
Intervention: Control preterm formula
Number of subjects: 37
Study 11398582 — intervention group
Group type: EXPERIMENTAL
Intervention: Divina (2 mg valerate estradiol and 10 mg medroxyprogesterone acetate)
Number of subjects: 0
Study 9267584 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace elements/zinc 20 mg
Number of subjects: 81
Study 9267584 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium 100 micrograms
Number of subjects: 81
Study 9267584 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins (vitamin C 120 mg; beta‐carotene 6 mg; alpha‐tocopherol 15 mg)
Number of subjects: 81
Study 9267584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of trace elements and vitamins at equal doses
Number of subjects: 81
Study 9267584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 8453855 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg every day)
Number of subjects: 12
Study 8453855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice a day)
Number of subjects: 12
Study 8453855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3087688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of 1 mg nitroglycerin
Number of subjects: 7
Study 3087688 — intervention group
Group type: COMPARATOR
Intervention: No intervention (tilting without collapse)
Number of subjects: 7
Study 30794607 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1054
Study 30794607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1054
Study 29505804 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal antidepressant monotherapy (imipramine or venlafaxine) for 7 weeks
Number of subjects: 85
Study 29505804 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent plasma level-targeted dose lithium addition for 4 weeks
Number of subjects: 85
Study 29505804 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent electroconvulsive therapy
Number of subjects: 85
Study 26555605 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 607
Study 26555605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 607
Study 24462108 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insole
Number of subjects: 40
Study 24462108 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study 22431703 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatment plus RFA
Number of subjects: 119
Study 22431703 — intervention group
Group type: COMPARATOR
Intervention: Systemic treatment alone
Number of subjects: 119
Study 19640958 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A Supplementation (VAS)
Number of subjects: 11722
Study 17548550 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutoring with memory training
Number of subjects: 11
Study 17548550 — intervention group
Group type: COMPARATOR
Intervention: Tutoring without memory training
Number of subjects: 11
Study 15779091 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline data used for trial design
Number of subjects: 0
Study 15779091 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of 'change from baseline'
Number of subjects: 0
Study 15779091 — intervention group
Group type: EXPERIMENTAL
Intervention: Various trial design strategies
Number of subjects: 0
Study 11912374 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac alone
Number of subjects: 64
Study 11912374 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac combined with alfentanil patient controlled analgesia
Number of subjects: 64
Study 9474633 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold compression dressings
Number of subjects: 40
Study 9474633 — intervention group
Group type: COMPARATOR
Intervention: Wool and crepe dressings
Number of subjects: 40
Study 7533517 — intervention group
Group type: EXPERIMENTAL
Intervention: FEMTX (fluorouracil, epidoxorubicin, methotrexate)
Number of subjects: 41
Study 7533517 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 41
Study 7533517 — intervention group
Group type: EXPERIMENTAL
Intervention: FEMTX
Number of subjects: 41
Study 1353540 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (20 micrograms, administered daily in a nasal spray)
Number of subjects: 59
Study 1353540 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (administered after buserelin treatment)
Number of subjects: 59
Study 1353540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 1353540 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 59
Study 6426830 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.2 mg/kg)
Number of subjects: 13
Study 6426830 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH (100 micrograms)
Number of subjects: 13
Study 6426830 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 13
Study 29951902 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention for breast cancer detection and screening
Number of subjects: 150
Study 29951902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study 29274507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) rich in olive oil, 35% of calories from fat (22% monounsaturated) and 50% from carbohydrates, for 1.5 years
Number of subjects: 805
Study 29274507 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) rich in olive oil, for 1.5 years
Number of subjects: 805
Study 29274507 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LF diet), for 1.5 years
Number of subjects: 805
Study 26771873 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course radiation (SC)
Number of subjects: 326
Study 26771873 — intervention group
Group type: COMPARATOR
Intervention: Long course chemoradiation (LC)
Number of subjects: 326
Study 24687848 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Number of subjects: 12
Study 24687848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24687848 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimally dosed medication
Number of subjects: 12
Study 23675990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented red ginseng (FRG)
Number of subjects: 93
Study 23675990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 20442989 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid decline group (RPD, n = 20)
Number of subjects: 38
Study 20442989 — intervention group
Group type: COMPARATOR
Intervention: Slow or absent decline group (SLW, n = 18)
Number of subjects: 38
Study 18597078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifeprunox 20 mg
Number of subjects: 589
Study 18597078 — intervention group
Group type: COMPARATOR
Intervention: Bifeprunox (5 mg, 10 mg)
Number of subjects: 589
Study 18597078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Number of subjects: 589
Study 18597078 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg
Number of subjects: 589
Study 18597078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 589
Study 16021194 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar anaesthesia
Number of subjects: 220
Study 16021194 — intervention group
Group type: COMPARATOR
Intervention: Oral diazepam, mefenamic acid, acetaminophen (alone or in combination)
Number of subjects: 220
Study 16021194 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of ketorolac tromethamine
Number of subjects: 220
Study 14508365 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (5.0 mg/kg orally, preoperatively, 2.5 mg/kg orally, two times a day, postoperatively)
Number of subjects: 71
Study 14508365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 14508365 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 71
Study 10961161 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg three times per day)
Number of subjects: 22
Study 10961161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 8672323 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% low‐molecular weight (LMW) hydroxyethylstarch solution (HES) in sepsis patients
Number of subjects: 60
Study 8672323 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin (HA) in sepsis patients
Number of subjects: 60
Study 8672323 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% low‐molecular weight (LMW) hydroxyethylstarch solution (HES) in trauma patients
Number of subjects: 60
Study 8672323 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% human albumin (HA) in trauma patients
Number of subjects: 60
Study 8672323 — intervention group
Group type: EXPERIMENTAL
Intervention: HES in sepsis patients
Number of subjects: 60
Study 8672323 — intervention group
Group type: EXPERIMENTAL
Intervention: HA in sepsis patients
Number of subjects: 60
Study 2666205 — intervention group
Group type: EXPERIMENTAL
Intervention: benztropine (mean dose 3.8 mg)
Number of subjects: 20
Study 2666205 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 14602 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate at maximum doses
Number of subjects: 0
Study 14602 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate at maximum subtoxic levels
Number of subjects: 0
Study 31033154 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent (BP-SES; Ultimaster)
Number of subjects: 456
Study 31033154 — intervention group
Group type: COMPARATOR
Intervention: Permanent polymer everolimus-eluting stent (PP-EES; Xience)
Number of subjects: 456
Study 30030779 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception condition (participants saw the color scale and an eye picture simultaneously)
Number of subjects: 0
Study 30030779 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory condition (participants matched the color of an eye to the color scale from memory)
Number of subjects: 0
Study 30030779 — intervention group
Group type: EXPERIMENTAL
Intervention: Label condition (participants labeled the eye orally before matching the color from memory)
Number of subjects: 0
Study 30030779 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 0
Study 27892728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel, cisplatin, cetuximab, and radiation
Number of subjects: 34
Study 26460660 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (250 mg at anaesthetic induction and 250 mg at initiation of cardiopulmonary bypass)
Number of subjects: 7507
Study 26460660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7507
Study 26460660 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 7507
Study 24004517 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention group
Number of subjects: 20
Study 24004517 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 20
Study 21551479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 150